Cancer Research Meeting Calendar Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takakuwa, T.
Right arrow Articles by Aozasa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takakuwa, T.
Right arrow Articles by Aozasa, K.
[Cancer Research 61, 1382-1385, February 15, 2001]
© 2001 American Association for Cancer Research

Carcinogenesis

Frequent Mutations of Fas Gene in Thyroid Lymphoma1

Tetsuya Takakuwa, Zhiming Dong, Hitoshi Takayama, Fumio Matsuzuka, Shigekazu Nagata and Katsuyuki Aozasa2

Departments of Pathology [T. T., Z. D., H. T., K. A.] and Genetics [S. N.], Osaka University Graduate School of Medicine, Osaka 565-0871, and Section of Surgery, Kuma Hospital, Kobe 650-0011, Japan [F. M.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Fas (Apo-1/CD95) is a cell-surface receptor involved in cell death signaling through binding of Fas ligand. Mutation of the Fas gene results in accumulation of lymphoid cells and thus might contribute to lymphomagenesis. Thyroid lymphoma (TL) is supposed to arise from active lymphoid cells formed in the preceding autoimmune chronic lymphocytic thyroiditis (CLTH). We examined the open reading frame of Fas cDNA in 11 cases of CLTH and 26 cases of TL. These patients were admitted to the hospital with varying degrees of goiter. All of the CLTH patients were female, with median age of 65 years, and all but five cases of TL were female, with median age of 61 years. Mutations of the Fas gene were detected in 3 (27.3%) of 11 cases of CLTH and 17 (65.4%) of 26 of TL. The Fas mutations comprised 18 frameshift, 3 missense, and 1 nonsense mutation. Frameshift mutations were caused by insertion of 1 bp (A) at nucleotide 1095 in 10 cases and by lack of exon 8 in 8 cases. The insertion of 1 bp (A) at nucleotide 1095 has never been reported in other kinds of malignancies. Thus, this might be unique in TL and CLTH and might be mutational hotspots in these diseases. All mutations occurred in the cytoplasmic region (death domain) known to be involved in the apoptotic signal transduction and thus could be loss-of-function mutations. These findings suggested that accumulation of lymphoid cells in CLTH with Fas mutation provides a basis for development of TL.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Fas (Apo-1/CD95) is a Mr 45,000 membrane protein belonging to the tumor necrosis factor receptor family and mediates programmed cell death (apoptosis) on trimerization induced by cross-linking by FasL3 (1, 2, 3) . Fas locates on the chromosome 10q24.1 and comprises 9 exons and 8 introns. It consists of 325 amino acids with a single transmembrane domain, including signal peptide. The 80-amino acid portion designated as a death-signaling domain is essential for apoptotic signal transduction (4) .

Fas is expressed on the surface of activated T and B lymphocytes, and Fas/FasL-induced apoptosis is important for eliminating autoreactive immature T cells during ontogenesis and for maintaining peripheral lymphocyte homeostasis (3 , 5) . The lpr mice that harbor deleterious mutations in the Fas gene show enlargement of lymph nodes and spleen attributable to accumulation of CD4- CD8- (double negative) T cells, exhibit B-cell lymphocytosis, and produce large amount of IgG and IgM autoantibodies, including anti-DNA antibodies and rheumatoid factor (6) . Children who carry inherited defects in the Fas gene exhibit a similar, albeit variable, pattern of phenotypes that have been collectively termed as ALPS (7, 8, 9, 10, 11, 12, 13) .

B-cell NHL is a particular neoplastic disease in which a malignant clone develops from the immune lymphoid system. Recent study indicated that resistance to Fas-mediated apoptosis is a widespread phenomenon in NHL, allowing the escape of malignant B cells from immune regulation (14 , 15) . Gronbaek et al. (16) reported the rather higher frequency of Fas mutations in lymphomas, especially in those with clinical features suggestive of autoimmune disease. Although this finding is interesting and might provide an insight into the mechanism of B-lymphomagenesis, localization and clinical backgrounds of autoimmune disease in each case were quite diverse, whereas the Fas gene mutation could not be detected in any cases of lymphoproliferative disorders associated with Sjögren syndrome and type II mixed cryoglobulinemia reported by Bertolo et al. (17) .

TL is a minor constituent of NHL, accounting for 2.5% of all of the cases of extranodal lymphomas in the series of Freeman et al. from North America (18) and 2.2% from Japan (19) . However, TL had attracted attention of investigators because of its putative origin from active lymphoid cells in autoimmune lymphocytic thyroiditis, i.e., Hashimoto’s thyroiditis or CLTH (20) . Follow-up studies confirmed an important role of CLTH in the development of TL (21 , 22) . Autoimmune disease can be divided into organ-specific and systemic forms, and CLTH is categorized as one of the organ-specific autoimmune disease.

Giordano et al. (23) reported that thyrocytes from patients with CLTH expressed both Fas and FasL, suggesting the potential involvement of these molecules in the pathogenesis of CLTH. In the current study, we examined the Fas mutations in CLTH and TL to clarify whether Fas mutations are involved in the pathogenesis of TL.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cases.
Thyroid specimens were collected from 26 patients with TL and 11 with CLTH. They were admitted with varying degrees of goiter to Kuma Hospital (Kobe City, Japan) during the period 1995–1998. Results of studies on microsatellite instability and k-ras and p53 mutations in a part of TL and CLTH cases were previously reported (24) . All of the CLTH patients were female, and all but 5 cases of TL were female patients. The age of the patients on admission ranged from 45 to 85 years (median, 65 years) in TL and 52 to 75 years (median, 61 years) in CLTH. All patients underwent surgery including total, partial thyroidectomy, or open biopsy, and the histological specimens were fixed in 10% formalin and routinely processed for paraffin-embedding. Samples in all of the cases were snap-frozen with or without OCT compound at -150°C and stored at -80°C until use. Criteria for the diagnosis of CLTH included increased consistency of the thyroid gland, occasional hypothyroidism, high level of thyroid-stimulating hormone, low 123I uptake, and the presence of antimicrosomal and/or antithyroglobulin antibodies in the serum. Histological findings of the CLTH included lymphocytic infiltration, usually forming lymphoid follicles with germinal centers, varying degrees of fibrosis, and oxyphilic change or squamous metaplasia of epithelial cells of the thyroid follicles. Lymphoma cells in all of the cases showed a B-cell immunophenotype, i.e., CD20+ and/or MB-1+, CD3-, or CD45RO-. TL were classified according to the revised European-American Classification for Lymphoid Neoplasms (REAL; Ref. 25 ); diffuse large B-cell lymphoma in 10 cases, follicle center cell lymphoma in 8, and marginal zone B-cell lymphoma of the extranodal type (MALT) in 8. In the majority of cases with TL, the presence of lymphoid follicles with a germinal center could be confirmed, indicating the preexisting CLTH.

Isolation of Total RNA, Reverse Transcription-PCR, and Detection of Mutations.
Tissue samples from TL and CLTH were homogenized, and total RNA was extracted in the presence of TRIzol reagent (Life Technologies, Inc., Rockville, MD). Those from normal leukocytes of the patients were not available. Five µg of total RNA were reverse-transcribed by random hexamer priming, and the indicated fragments were amplified by 35 cycles in a thermocycler (Model 9700 thermocycler; Applied Biosystems, Foster City, CA). The primers were selected to amplify the Fas open reading frame (Fas full) or to amplify two segments named Fas I and II (Table 1)Citation . PCR products were purified using QIAquick PCR Purification Kit (Qiagen, Santa Clarita, CA) and cloned in the pCR 2.1-TOPO (Invitrogen, San Diego, CA). To control potential PCR error, 8 to 12 clones from three different PCR reactions (Fas full, Fas I, and Fas II) were sequenced individually. When common mutations were found in more than two PCR results, we regarded them as definite mutations. Frequency of mutations among clones ranged from 12.5 to 77.3%. Sequencing was performed by the dideoxy chain termination method using the DNA sequencing kit (Applied Biosystems). The samples were analyzed by the Genetic Analyzer (ABI PRISM 310'; Applied Biosystems). Ampli Taq Gold DNA polymerase (Applied Biosystems) and platinum pfx DNA polymerase (Life Technologies) were used for amplification of the Fas I and II segments and the Fas full segment, respectively.


View this table:
[in this window]
[in a new window]

  		Table 1 Oligonucleotide primers used for PCR reactions

 
Detection of Mutations in the Exon/Intron Boundary of Exon 8.
Genomic DNA extracted from the frozen tissues were subjected to PCR with the oligonucleotide primers, 8F1 and 8R1 or 8F2 and 8R2 (Table 1)Citation , which flank exon 8. PCR products were cloned in the pCR 2.1-TOPO (Invitrogen). Eight to 12 clones were sequenced.

Immunohistochemical Detection of Fas Protein.
Immunohistochemical study on the paraffin sections was carried out using the avidin-biotin-peroxidase complex method. For detection of Fas protein, mouse monoclonal antihuman Fas antibody (4B4-B3), which recognizes the extracellular domain of Fas, was prepared by S. Nagata.4


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Mutation of the Fas Gene.
Mutations of the Fas gene were detected in 3 (27.3%) of 11 cases of CLTH and 17 (65.4%) of 26 of TL (Table 2)Citation . Detection frequency was significantly higher in TL than in CLTH cases by Fisher’s exact probability test (P < 0.05). Mutations were more frequently found in cases with marginal zone B-cell lymphoma and follicle center cell lymphoma, although the difference in frequency among each histological type of lymphoma was not significant. All cases had mutations in the death domain. Two cases (cases 2 and 16) had two different mutations (Table 3)Citation .


View this table:
[in this window]
[in a new window]

  		Table 2 Distribution of Fas mutations according to the histological subtype

 

View this table:
[in this window]
[in a new window]

  		Table 3 Fas mutations in TL

 
Frameshift Mutations.
The Fas gene has a 6-(A) tract from nucleotide 1088 to 1094 of the Fas cDNA sequence (Ref. 26 ; GenBank accession no. M67454). Nine cases of TL showed insertion of 1 bp (A) at nucleotide 1095 that resulted in a frame shift. As a result, a stop codon was introduced at residue 303. No cases had mutations in a 7-(T) tract from nucleotide 591 to 597 of the Fas coding sequence. Six cases of TL showed a 25-bp deletion from nucleotide 846 to 870, which corresponded to exon 8. Lack of exon 8 also result in a frame shift, which generated a stop codon at residue 221. As a result, the whole intracytoplasmic death domain was deleted.

Mutations in the acceptor splice site of Fas intron 7 or in the donor spice site of exon 8 may cause the splice variant transcripts to lack exon 8. To examine this hypothesis, genomic DNA from the patients was amplified using primers flanking exon 8, cloned, and then sequenced. One case (case 39) had a transition of the invariable T at position +2 of the donor splice site of intron 8, which resulted in exon skipping. Three cases (cases 2, 3, and 60) had mutations in the consensus sequence of the acceptor splice site of intron 7 and one (cases 8) had the donor splice site of intron 8, although it is not certain whether these mutations cause exon-skipping or not (data not shown).

Point Mutations.
Three of the point mutations in TL were missense ones, which caused substitutions of nonconserved amino acids. All mutations were detected in exon 9, which encodes the death domain region of the Fas receptor. Two different transversions (G to A and G to C) at position 972, one causing the substitution of Asp with Asn and the other Asp with His at codon 244, were found in two TL cases, suggesting that this site might also represent a mutational hotspot. One mutation introduced premature termination signals at codon 216 within the death domain.

In CLTH cases, two showed a 25-bp deletion from nucleotide 846 to 870, which corresponded to exon 8. Genomic DNA from the same cases (cases 18 and 25) also had mutations located in the splice-site consensus sequences of exon 8, although it is not certain whether these mutations really cause exon-skipping (data not shown). One case showed insertion of 1 bp (A) at nucleotide 1095.

Immunohistochemistry.
Fas protein was expressed in the lymphoma cells and in the infiltrating reactive lymphoid cells, including germinal center cells in 15 (58%) of 26 TL cases and in the infiltrating lymphoid cells in 5 (45%) of 11 CLTH cases. There were no prominent differences in the positive rate of lymphoma cells among each histological type. Expression of Fas protein was more frequent in the lymphoma cases with the mutated Fas gene, 14 (70%) of 20 cases, than in the nonmutated cases, 6 (35%) of 17 cases (P < 0.05, Table 4Citation ).


View this table:
[in this window]
[in a new window]

  		Table 4 Fas protein expression according to Fas gene mutations

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Fas mutations have been reported in the lymphoid malignancies: ~10% of cases with multiple myeloma (27) and 11% with sporadic NHL (16) . In the current study, mutations of the Fas gene were detected in 3 (27.3%) of 11 cases of CLTH and 17 (65.4%) of 26 of TL, showing a much higher frequency in these diseases than that in the previous study on the nonthyroid malignancies. In the thyroid tissues, resistance to Fas-induced cell death might be an important step in cellular accumulation, because FasL was shown to be constitutively expressed in thyrocytes from normal and CLTH thyroid tissues (23) . Therefore, lymphoid cells with Fas mutations might be allowed to escape from apoptosis induced by Fas-FasL interactions between thyrocytes, infiltrated T cells, and B lymphocytes. Because TL is supposed to arise from active lymphoid cells formed in CLTH, accumulation of Fas-mutated lymphoid cells in CLTH lesions might make a basis for development of TL.

The Fas mutations in the current series comprised 18 frameshifts, which were caused by a 1-bp insertion in 10 cases (9 TL and 1 CLTH cases) and by lack of exon 8 in eight cases. Mutations in all of the cases occurred in the death domain known to be involved in the apoptotic signal transduction; thus, the mutations in our cases should result in resistance of lymphoid cells to apoptosis. In the previous studies on lymphoid malignancies (16 , 27, 28, 29) as well as ALPS (7, 8, 9, 10, 11, 12, 13 , 30) , the majority of mutations were located in the death domain, indicating that Fas-induced apoptosis also could be altered by mutations in the Fas genes in these cases, although several studies showed relatively rare occurrence of Fas mutations in lymphoproliferative diseases (17 , 31 , 32) .

One base insertion within a polyadenine tract was found in 9 TL and one CLTH cases. The wild-type Fas gene has a 6-(A) tract from nucleotide 1088 to 1094, but these mutated cases had 7-(A) tract by insertion of 1 bp (A) at nucleotide 1095. The same kind of mutation has never been reported in other kinds of malignancies, including multiple myeloma (27) , sporadic NHL (16) , and adult T-cell leukemia (28 , 29) as well as ALPS (7, 8, 9, 10, 11, 12, 13 , 30) . Meanwhile, the mononucleotide tract in the coding sequence is a mutational hotspot in many kinds of genes, such as transforming growth factor ß receptor type II gene (33) and insulin-like growth factor receptor type II gene (34) . These findings suggested that the insertion of 1 bp (A) at nucleotide 1095 was unique in TL and CLTH and might be a mutational hotspot in these diseases. A 1-bp insertion at nucleotide 1095 results in a frame shift at codon 285 and introduces a stop codon at residue 303. Because this site is quite close to the terminal site, whether this mutation would cause loss of function is equivocal, although Ito et al. (4) demonstrated that the 130-amino acid portion from 175 to 304 in the cytoplasmic region of the human Fas gene is essential for the Fas-antigen triggered apoptotic signal transduction.

Six TL and 2 CLTH cases lacked exon 8 as splicing variants of the Fas gene. These variants have been reported in the apoptosis-resistant clone derived from human T-cell lymphoma cell line HUT78 (35) and in cases of NHL that developed in two patients, one with CLTH and Sjögren syndrome and the other with rheumatoid arthritis (16) . These variants also are known to interfere with Fas-mediated apoptosis signaling in a dominant-negative fashion. Recently, two studies showed that deletion of exon 8 was a loss-of-function mutation (13 , 14) . Thus, this kind of splicing variant might be characteristically found in lymphoid cells involved in systemic and organ-specific autoimmune diseases and in developing lymphoma from them.

Most of the mutations identified in the current cases are likely to disrupt or alter the normal structure and/or function of Fas. Mutations in 19 cases are predicted to cause frameshifts (10 cases), aberrant RNA splicing (8 cases), and premature termination (1 case) and thus are judged as typical loss-of-function mutations. Previous studies showed that the genetic defects resulting in the production of a truncated form of proteins might be able to confer a dominant-negative effect (9 , 13 , 14) . The remaining mutations were missense variants that resulted in substitutions of nonconservative amino acid. Three missense mutations (cases 7, 16, and 19) within the region encoding the Fas death domain affected the codons that are highly conserved in evolution (4) . Furthermore, alteration of codon 244, found in cases 7 and 16, has been reported in ALPS (7, 8, 9, 10, 11, 12, 13, 14) and NHL (16) . This mutation caused the reduced trimerization of Fas induced by cross-linking of FasL and its binding to FADD/MORT1, which is essential for the apoptotic signal transduction (36) .

There were no prominent differences in the histological and clinical findings between the Fas-mutated and nonmutated cases. Meanwhile, Fas protein was more frequently expressed in the Fas-mutated cases (65% of cases) than in the nonmutated cases. Whether alterations in the expression and/or function of components situated downstream of the same pathway of Fas-mediated apoptosis, such as FADD/MORT1 (37 , 38) , Caspase 8 (39 , 40) , and FLICE-inhibitory proteins (41) , cause resistance to the apoptosis in cases with the wild-type Fas gene or not will be subject to future studies.

In conclusion, the results of our study provide direct evidence that the Fas-mediated apoptotic pathway is abrogated in 65.4% of TL and 27.3% of CLTH cases. These findings suggested that accumulation of lymphoid cells in CLTH with the Fas mutation provide a basis for development of TL.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by a grant from the Vehicle Racing Commemorative Foundation and Grants 09670184, 09770148, 10042005, 10151225, 11470353, 11670212, and 11680546 from the Ministry of Education, Science, and Culture, Japan. Back

2 To whom requests for reprints should be addressed, at Department of Pathology (C3), Osaka University Medical school, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-3710; Fax: 81-6-6879-3713; E-mail: aozasa{at}molpath.med.osaka-u.ac.jp Back

3 The abbreviations used are: FasL, Fas ligand; NHL, non-Hodgkin’s lymphoma; ALPS, autoimmune lymphoproliferative syndrome; TL, thyroid lymphoma; CLTH, chronic lymphocytic thyroiditis; MALT, mucosa-associated lymphoid tissue. Back

4 S. Nagata, unpublished data. Back

Received 5/ 1/00. Accepted 12/ 7/00.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.. Cell, 75: 1169-1178, 1993.[Medline]
  2. Nagata S., Golstein P. The Fas death factor.. Science (Washington DC), 267: 1449-1456, 1995.[Abstract/Free Full Text]
  3. Nagata S. Apoptosis by death factor.. Cell, 88: 355-665, 1997.[Medline]
  4. Itoh N., Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J. Biol. Chem., 268: 10932-10937, 1993.[Abstract/Free Full Text]
  5. Rathmell J. C., Townsend S. E., Xu J. C., Flavell R. A., Goodnow C. C. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor.. Cell, 87: 319-329, 1996.[Medline]
  6. Watanabe F. R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis.. Nature (Lond.), 356: 314-317, 1992.[Medline]
  7. Bettinardi A., Brugnoni D., Quiros-Roldan E., La Malagoli A., Grutta S., Correra A., Notarangelo L. D. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis.. Blood, 89: 902-909, 1997.[Abstract/Free Full Text]
  8. Drappa J., Vaishnaw A. K., Sullivan K. E., Chu J. L., Elkon K. B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity.. N. Engl. J. Med., 335: 1643-1649, 1996.[Abstract/Free Full Text]
  9. Fisher G. H., Rosenberg F. J., Straus S. E., Dale J. K., Middleton L. A., Lin A. Y., Strober W., Lenardo M. J., Puck J. M. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.. Cell, 81: 935-946, 1995.[Medline]
  10. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I. A., Debatin K. M., Fischer A., de Villartay J. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.. Science (Washington DC), 268: 1347-1349, 1995.[Abstract/Free Full Text]
  11. Sneller M. C., Wang J., Dale J. K., Strober W., Middelton L. A., Choi Y., Fleisher T. A., Lim M. S., Jaffe E. S., Puck J. M., Lenardo M. J., Straus S. E. Clinical, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.. Blood, 89: 1341-1348, 1997.[Abstract/Free Full Text]
  12. Vaishnaw A. K., Orlinick J. R., Chu J. L., Krammer P. H., Chao M. V., Elkon K. B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations.. J. Clin. Investig., 103: 355-363, 1999.[Medline]
  13. Martin D. A., Zheng L., Siegel R. M., Huang B., Fisher G. H., Wang J., Jackson C. E., Puck J. M., Dale J., Straus S. E., Peter M. E., Krammer P. H., Fesik S., Lenardo M. J. Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia.. Proc. Natl. Acad. Sci. USA, 96: 4552-4557, 1999.[Abstract/Free Full Text]
  14. Plumas J., Jacob M. C., Chaperot L., Molens J. P., Sotto J. J., Bensa J. C. Tumor B cells from non-Hodgkin’s lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis.. Blood, 91: 2875-2885, 1998.[Abstract/Free Full Text]
  15. Xerri L., Bouabdallah R., Devilard E., Hassoun J., Stoppa A. M., Birg F. Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin’s lymphomas and is moderately increased by CD40 ligation.. Br. J. Cancer, 78: 225-232, 1998.[Medline]
  16. Gronbaek K., Straten P. T., Ralfkiaer E., Ahrenkiel V., Andersen M. K., Hansen N. E., Zeuthen J., Hou J. K., Guldberg P. Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity.. Blood, 92: 3018-3024, 1998.[Abstract/Free Full Text]
  17. Bertolo F., De Vita S., Dolcetti R., Carbone A., Ferraccioli G. F., Bartoli E., Boiocchi M. Lack of Fas and Fas-L mutations in patients with lymphoproliferative disorders associated with Sjögren syndrome and type II mixed cryoglobulinemia.. Clin. Exp. Rheumatol., 17: 339-342, 1999.[Medline]
  18. Freeman C., Berg J. W., Cutler S. J. Occurrence and prognosis of extranodal lymphomas.. Cancer (Phila.), 29: 252-260, 1972.[Medline]
  19. Aozasa K., Tsujimoto M., Sakurai M., Honda M., Yamashita K., Hanada M., Sugimoto A. Non-Hodgkin’s lymphomas in Osaka, Japan.. Eur. J. Cancer Clin. Oncol., 21: 487-492, 1985.[Medline]
  20. Volpe R. Thyroiditis: current views of pathogenesis.. Med. Clin. North Am., 59: 1163-1175, 1975.[Medline]
  21. Holm L. E., Blomgren H., Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis.. N. Engl. J. Med., 312: 601-604, 1985.[Abstract]
  22. Kato I., Tajima K., Suchi T., Aozasa K., Matsuzuka F., Kuma K., Tominaga S. Chronic thyroiditis as a risk factor of B-cell lymphoma in the thyroid gland.. Jpn. J. Cancer Res., 76: 1085-1090, 1985.[Medline]
  23. Giordano C., Stassi G., De Maria R., Todaro M., Richiusa P., Papoff G., Ruberti G., Bagnasco M., Testi R., Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis.. Science (Washington DC), 275: 960-963, 1997.[Abstract/Free Full Text]
  24. Takakuwa T., Hongyo T., Syaifudin M., Kanno T., Matsuzuka F., Narabayashi I., Nomura T., Aozasa K. Microsatellite instability and k-ras, p53 mutations in thyroid lymphoma.. Jpn. J. Cancer Res., 91: 280-286, 2000.[Medline]
  25. Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan J. K., Cleary M. L., Delsol G., De Wolf-Peeters C., Falini B., Gatter K. C. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84: 1361-1392, 1994.[Free Full Text]
  26. Itoh N., Yonehara S., Ishii A., Yonehara M., Mizushima S., Sameshima M., Hase A., Seto Y., Nagata S. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis.. Cell, 66: 233-243, 1991.[Medline]
  27. Landowski T. H., Qu N., Buyuksal I., Painter J. S., Dalton W. S. Mutations in the Fas antigen in patients with multiple myeloma.. Blood, 90: 4266-4270, 1997.[Abstract/Free Full Text]
  28. Maeda T., Yamada Y., Moriuchi R., Sugahara K., Tsuruda K., Joh T., Atogami S., Tsukasaki K., Tomonaga M., Kamihira S. Fas gene mutation in the progression of adult T cell leukemia.. J. Exp. Med., 189: 1063-1071, 1999.[Abstract/Free Full Text]
  29. Tamiya S., Etoh K., Suzushima H., Takatsuki K., Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells.. Blood, 91: 3935-3942, 1998.[Abstract/Free Full Text]
  30. Nagata S. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.. J. Hum. Genet., 43: 2-8, 1998.[Medline]
  31. Bertoni F., Conconi A., Luminari S., Realini C., Roggero E., Baldini L., Carobbio S., Cavalli F., Neri A., Zucca E. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas.. Leukemia, 14: 446-448, 2000.[Medline]
  32. Xerri L., Carbuccia N., Parc P., Birg F. Search for rearrangements and/or allelic loss of the Fas/APO-1 gene in 101 human lymphomas.. Am. J. Clin. Pathol., 104: 424-230, 1995.[Medline]
  33. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R. S., Zborowska E., Kinzler K. W., Vogelstein B. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.. Science (Washington DC), 268: 1336-1338, 1995.[Abstract/Free Full Text]
  34. Souza R. F., Appel R., Yin J., Wang S., Smolinski K. N., Abraham J. M., Zou T. T., Shi Y. Q., Lei J., Cottrell J., Cymes K., Biden K., Simms L., Leggett B., Lynch P. M., Frazier M., Powell S. M., Harpaz N., Sugimura H., Young J., Meltzer S. J. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumors.. Nat. Genet., 14: 255-257, 1996.[Medline]
  35. Cascino I., Papoff G., De Maria R., Testi R., Ruberti G. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis.. J. Immunol., 156: 13-17, 1996.[Abstract]
  36. Huang B., Eberstadt M., Olejniczak E. T., Meadows R. P., Fesik S. W. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain.. Nature (Lond.), 384: 638-641, 1996.[Medline]
  37. Chinnaiyan A. M., O’Rourke K., Tewari M., Dixit V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.. Cell, 81: 505-512, 1995.[Medline]
  38. Boldin M. P., Goncharov T. M., Goltsev Y. V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.. Cell, 85: 803-815, 1996.[Medline]
  39. Boldin M. P., Varfolomeev E. E., Pancer Z., Mett I. L., Camonis J. H., Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain.. J. Biol. Chem., 270: 7795-7798, 1995.[Abstract/Free Full Text]
  40. Muzio M., Chinnaiyan A. M., Kischkel F. C., O’Rourke K., Shevchenko A., Ni J., Scaffidi C., Bretz J. D., Zhang M., Gentz R., Mann M., Krammer P. H., Peter M. E., Dixit V. M. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death–inducing signaling complex.. Cell, 85: 817-827, 1996.[Medline]
  41. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F., Mattmann C., Burns K., Bodmer J. L., Schroter M., Scaffidi C., Krammer P. H., Peter M. E., Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors.. Nature (Lond.), 386: 517-521, 1997.[Medline]



This article has been cited by other articles:


Home page
 BloodHome page
F. Suarez, O. Lortholary, O. Hermine, and M. Lecuit
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Blood, April 15, 2006; 107(8): 3034 - 3044.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. W. Wolkersdorfer, C. Marx, J. Brown, S. Schroder, M. Fussel, E. P. Rieber, E. Kuhlisch, G. Ehninger, and S. R. Bornstein
Prevalence of HLA-DRB1 Genotype and Altered Fas/Fas Ligand Expression in Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1768 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Wohlfart, D. Sebinger, P. Gruber, J. Buch, D. Polgar, G. Krupitza, M. Rosner, M. Hengstschlager, M. Raderer, A. Chott, et al.
FAS (CD95) Mutations Are Rare in Gastric MALT Lymphoma but Occur More Frequently in Primary Gastric Diffuse Large B-Cell Lymphoma
Am. J. Pathol., March 1, 2004; 164(3): 1081 - 1089.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Sanchez-Beato, A. Sanchez-Aguilera, and M. A. Piris
Cell cycle deregulation in B-cell lymphomas
Blood, February 15, 2003; 101(4): 1220 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. Shen, A. C. T. Liang, L. Lu, W. Y. Au, Y.-L. Kwong, R. H. S. Liang, and G. Srivastava
Frequent Deletion of Fas Gene Sequences Encoding Death and Transmembrane Domains in Nasal Natural Killer/T-Cell Lymphoma
Am. J. Pathol., December 1, 2002; 161(6): 2123 - 2131.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Takayama, T. Takakuwa, Y. Tsujimoto, Y. Tani, N. Nonomura, A. Okuyama, S. Nagata, and K. Aozasa
Frequent Fas Gene Mutations in Testicular Germ Cell Tumors
Am. J. Pathol., August 1, 2002; 161(2): 635 - 641.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takakuwa, T.
Right arrow Articles by Aozasa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takakuwa, T.
Right arrow Articles by Aozasa, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online